A stronger antigen‐specific CTL immune response capable of suppressing CRC growth and improving animal survival was previously reported in MC38‐ and CT26‐bearing mice when antigen and adjuvants were delivered by adjuvant particulate nanovaccines, in contrast to soluble molecules and other controls.[39b–f] Nanovaccines co‐entrapping both CpG‐ODN and Poly(I:C) allowed the multi‐targeting synergistic co‐stimulatory effect due to the simultaneous engagement of both TLR9 and TLR3, respectively, at the endosomal compartment. The gene discussed is TLR3; the disease is colorectal carcinoma.